48P Real World 9LA study
Presented by Prof Dr Lore Decoster (University Hospital Brussels, Belgium)
The CheckMate 9LA study demonstrated superior efficacy of ipilimumab plus nivolumab (IPI/NIVO) and two cycles of platinum doublet chemotherapy compared to chemotherapy alone in advanced NSCLC. In this trial, the most pronounced benefit was observed in patients with PD-L1 negative tumors and in patients with a squamous tumor histology. The retrospective Real World 9LA study was subsequently set up to collect real world data on the efficacy and toxicity of the 9LA regimen in PD-L1 negative, advanced NSCLC.
With an objective response rate of 40%, a median progression free survival (PFS) of 5.5 months and a median overall survival of 22.9 months, the RW 9LA study was able to reproduce the results from CheckMate 9LA in a real-world setting. The study did not reveal new safety signals. Nevertheless, Prof Lore Decoster (University Hospital Brussels) underscored that immune related adverse events were frequent (65%, 22.5% grade ≥3) and should be monitored closely when this regimen is being used.
References:
Decoster L et al. ELCC 2025. Abstract 48P.
